Beta-blockers are a cornerstone of therapy across multiple cardiovascular conditions including hypertension, angina, post-MI, and heart failure, though they remain underutilized due to misconceptions about tolerability.
Answers are grounded in this paper and cite their sources.
Supports beta-blocker use across hypertension, angina, post-MI, and HF; leaves open implementation strategies to address underutilization.
β -Blockers are widely used in cardiovascular medicine. In patients with hypertension, β-blockers show beneficial effects on clinical end points of stroke and coronary heart disease prevention and mortality. β-Blockers also are well established in improving exercise tolerance and decreasing the number and duration of anginal attacks in patients with angina pectoris. Based on evidence showing reduced mortality and morbidity, β-blockers are the cornerstone of therapy after acute myocardial infarction. Unfortunately, presumption of poor tolerance has left these drugs underutilized in this clinical setting, despite data that indicate a wide range of tolerability. The use of β-blockers in patients with congestive heart failure results in beneficial hemodynamic effects and symptomatic improvement. Among factors that should be considered when selecting a β-blocker for an individual patient are demonstrated efficacy of the drug in a specific indication, tolerability, product formulation and duration of action, and the presence or absence of specific properties such as cardioselectivity. (Arch Intern Med. 1996;156:1267-1276)
No takes yet. Share an insight, caveat, or question.
Sidney Goldstein (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: